Literature DB >> 1530822

Interleukin-1 receptor antagonist production by human keratinocytes.

C F Bigler1, D A Norris, W L Weston, W P Arend.   

Abstract

Human keratinocytes produce biologically active pro-IL-1 alpha and inactive pro-IL-1 beta with most protein remaining intracellular. IL-1 receptor antagonist (IL-1ra) is a newly described member of the IL-1 family that is secreted by stimulated monocytes and binds competitively to IL-1 receptors without stimulating target cells. We examined the characteristics of IL-1ra production by cultured human keratinocytes. By ELISA, keratinocyte lysates contained 390 ng IL-1ra/mg total protein with little IL-1ra detected in supernatants. In contrast, monocytes produced 297 ng IL-1ra/mg total protein during 24 h of culture on adherent IgG with about half of the IL-1ra detected in supernatants. By Western blot analysis, keratinocyte IL-1ra was approximately 20 kD in size and was slightly larger than recombinant monocyte IL-1ra. In contrast to monocytes, human keratinocyte IL-1ra was not secreted in 22-25-kD molecular weight glycosylated forms. Affinity-purified keratinocyte IL-1ra exhibited identical biologic activity to recombinant monocyte IL-1ra, each inhibiting IL-1-dependent augmentation of murine thymocyte proliferation to the same degree per amount of protein. An IL-1ra mRNA of 1.8 kb was detected by Northern blot analysis in RNA extracted from keratinocytes. In order to determine the effect of differentiation on IL-1 and IL-1ra production, human keratinocytes were cultured for 72 h in low (0.03 mM), medium (0.15 mM), or high (1.0 mM)-calcium concentrations. The absolute amounts of IL-1ra increased twofold and the ratio of IL-1ra to IL-1 alpha in keratinocyte lysates increased from approximately 12:1 to 25:1 during differentiation. These results indicate that keratinocytes constitutively produce large amounts of a biologically active intracellular variant of IL-1ra that increase with differentiation. IL-1ra released during keratinocyte damage may be important in modifying the inflammatory effects of IL-1 alpha in human skin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1530822     DOI: 10.1111/1523-1747.ep12494196

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  20 in total

1.  DIRA, DITRA, and new insights into pathways of skin inflammation: what's in a name?

Authors:  Edward W Cowen; Raphaela Goldbach-Mansky
Journal:  Arch Dermatol       Date:  2012-03

2.  Novel interleukin-1 receptor antagonist exon polymorphisms and their use in allele-specific mRNA assessment.

Authors:  F E Clay; J K Tarlow; M J Cork; A Cox; M J Nicklin; G W Duff
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

3.  IL-1ra and IL-1 production in human oral mucosal epithelial cells in culture: differential modulation by TGF-beta1 and IL-4.

Authors:  S Perrier; B Kherratia; C Deschaumes; S Ughetto; J-L Kemeny; M Baudet-Pommel; B Sauvezie
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

4.  How Can Interleukin-1 Receptor Antagonist Modulate Distinct Cell Death Pathways?

Authors:  Angelo Spinello; Elena Vecile; Antonio Abbate; Aldo Dobrina; Alessandra Magistrato
Journal:  J Chem Inf Model       Date:  2019-01-10       Impact factor: 4.956

5.  Keratinocyte expression of the type 2 interleukin 1 receptor mediates local and specific inhibition of interleukin 1-mediated inflammation.

Authors:  T Rauschmayr; R W Groves; T S Kupper
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

6.  Substance P and keratinocyte activation markers: an in vitro approach.

Authors:  J Viac; A Gueniche; J D Doutremepuich; U Reichert; A Claudy; D Schmitt
Journal:  Arch Dermatol Res       Date:  1996-02       Impact factor: 3.017

7.  Interleukin-1 receptor antagonist in normal and psoriatic epidermis.

Authors:  C Hammerberg; W P Arend; G J Fisher; L S Chan; A E Berger; J S Haskill; J J Voorhees; K D Cooper
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

8.  The production of interleukin-1 receptor antagonist by human bronchogenic carcinoma.

Authors:  D R Smith; S L Kunkel; T J Standiford; S W Chensue; M W Rolfe; M B Orringer; R I Whyte; M D Burdick; J M Danforth; A R Gilbert
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

9.  Detection of interleukin-1 receptors in human epidermis. Induction of the type II receptor after organ culture and in psoriasis.

Authors:  R W Groves; L Sherman; H Mizutani; S K Dower; T S Kupper
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

10.  Interleukin 1 receptor antagonist gene polymorphism association with lichen sclerosus.

Authors:  F E Clay; M J Cork; J K Tarlow; A I Blakemore; C I Harrington; F Lewis; G W Duff
Journal:  Hum Genet       Date:  1994-10       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.